NVSNovartis PharmaceuticalsSigning up patients
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 232 (planned)
- Started
- Nov 24, 2023
- Main results expected
- May 31, 2028
- Fully finished
- May 2, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage 2:Radiological response rate at Week 24 of Stage 2 (adult and pediatric (6 - 17 years of age) participants)
Measured over: Baseline, Week 24
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05948943 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC